The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Deep-PK: deep learning for small molecule pharmacokinetic and toxicity prediction
Open accessAbstract
Evaluating pharmacokinetic properties of small molecules is considered a key feature in most drug development and high-throughput screening processes. Generally, pharmacokinetics, which represent the fate of drugs in the human body, are described from four perspectives: absorption, distribution, metabolism and excretion—all of which are closely related to a fifth perspective, toxicity (ADMET). Since obtaining ADMET data from in vitro, in vivo or pre-clinical stages is time consuming and expensive, many efforts have been made to predict ADMET properties via computational approaches. However, the majority of available methods are limited in their ability to provide pharmacokinetics and toxicity for diverse targets, ensure good overall accuracy, and offer ease of use, interpretability and extensibility for further optimizations. Here, we introduce Deep-PK, a deep learning-based pharmacokinetic and toxicity prediction, analysis and optimization platform. We applied graph neural networks and graph-based signatures as a graph-level feature to yield the best predictive performance across 73 endpoints, including 64 ADMET and 9 general properties. With these powerful models, Deep-PK supports molecular optimization and interpretation, aiding users in optimizing and understanding pharmacokinetics and toxicity for given input molecules. The Deep-PK is freely available at https://biosig.lab.uq.edu.au/deeppk/.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scikit-learn: Machine Learning in Python
Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Müller, A., Nothman, J., Louppe, G., et al. (2012) · arXiv · doi:10.48550/arxiv.1201.0490 · Cited by 71,016
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00104 · Cited by 5,716
Self-citationInnovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab255 · Cited by 2,857
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties
Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., Liu, G., Lee, P. W., & Tang, Y. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300367a · Cited by 2,222
Analyzing Learned Molecular Representations for Property Prediction
Yang, K., Swanson, K., Jin, W., Coley, C., Eiden, P., Gao, H., Guzman-Perez, A., Hopper, T., Kelley, B., Mathea, M., et al. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00237 · Cited by 1,923
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Dong, J., Wang, N.-N., Yao, Z.-J., Zhang, L., Cheng, Y., Ouyang, D., Lu, A.-P., & Cao, D.-S. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0283-x · Cited by 889
Derivation and Validation of Toxicophores for Mutagenicity Prediction
Kazius, J., McGuire, R., & Bursi, R. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040835a · Cited by 666
High drug attrition rates—where are we going wrong?
Hutchinson, L., & Kirk, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.34 · Cited by 517
Drug discovery in pharmaceutical industry: productivity challenges and trends
Khanna, I. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.007 · Cited by 479 · cited 1×
“Evaluating, understanding and optimizing pharmacokinetic and toxicity properties under the umbrella of ADMET (absorption, distribution, metabolism, elimination and toxicity) categories have become essential for reducing attrition rates in later phases of drug research and development ( 3 ,16–21 ).”
BackgroundDrugs, Devices, and the FDA: Part 1
Van Norman, G. A. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.002 · Cited by 366
The Role of Absorption, Distribution, Metabolism, Excretion and Toxicity in Drug Discovery
Lin, J., Sahakian, D., de Morais, S., Xu, J., Polzer, R., & Winter, S. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033452096 · Cited by 327
Kiriiri, G. K., Njogu, P. M., & Mwangi, A. N. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00047-9 · Cited by 227
Van Norman, G. A. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.06.003 · Cited by 223
Towards reproducible computational drug discovery
Schaduangrat, N., Lampa, S., Simeon, S., Gleeson, M. P., Spjuth, O., & Nantasenamat, C. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-0408-x · Cited by 208
Improving and Accelerating Drug Development for Nervous System Disorders
Pankevich, D. E., Altevogt, B. M., Dunlop, J., Gage, F. H., & Hyman, S. E. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.007 · Cited by 206
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.03.010 · Cited by 186
Addressing toxicity risk when designing and selecting compounds in early drug discovery
Segall, M. D., & Barber, C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.01.006 · Cited by 171
Lost in Translation: The Gap in Scientific Advancements and Clinical Application
Fernandez-Moure, J. S. (2016) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00043 · Cited by 127
How can attrition rates be reduced in cancer drug discovery?
Moreno, L., & Pearson, A. D. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.768984 · Cited by 127
The Critical Role of Passive Permeability in Designing Successful Drugs
Di, L., Artursson, P., Avdeef, A., Benet, L. Z., Houston, J. B., Kansy, M., Kerns, E. H., Lennernäs, H., Smith, D. A., & Sugano, K. (2020) · ChemMedChem · doi:10.1002/cmdc.202000419 · Cited by 119
Modeling Physico-Chemical ADMET Endpoints with Multitask Graph Convolutional Networks
Montanari, F., Kuhnke, L., ter Laak, A., & Clevert, D.-A. (2019) · Molecules · doi:10.3390/molecules25010044 · Cited by 118
Challenges and opportunities with modelling and simulation in drug discovery and drug development
Lavé, T., Parrott, N., Grimm, H. P., Fleury, A., & Reddy, M. (2007) · Xenobiotica · doi:10.1080/00498250701534885 · Cited by 115
ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
Tsaioun, K., Bottlaender, M., & Mabondzo, A. M. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s1 · Cited by 111
Basavaraj, S., & Betageri, G. V. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.12.003 · Cited by 110
Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development
Petrova, E. (2013) · International series in quantitative marketing · doi:10.1007/978-1-4614-7801-0_2 · Cited by 109
Pires, D. E. V., de Melo-Minardi, R. C., dos Santos, M. A., da Silveira, C. H., Santoro, M. M., & Meira, W. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-s4-s12 · Cited by 104
Wei, Y., Li, S., Li, Z., Ziwei, W., & Lin, J. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac192 · Cited by 97
The FDA's Drug Review Process: Ensuring Drugs are Safe and Effective
Meadows, M. (2002) · PsycEXTRA Dataset · doi:10.1037/e542562006-004 · Cited by 85
Accurate prediction of human drug toxicity: a major challenge in drug development
Li, A. P. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.09.008 · Cited by 82
Vrbanac, J., & Slauter, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00003-7 · Cited by 77
toxCSM: comprehensive prediction of small molecule toxicity profiles
de Sá, A. G. C., Long, Y., Portelli, S., Pires, D. E. V., & Ascher, D. B. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac337 · Cited by 61
Self-citationMIMOSA: Multi-constraint Molecule Sampling for Molecule Optimization
Fu, T., Xiao, C., Li, X., Glass, L. M., & Sun, J. (2021) · Proceedings of the AAAI Conference on Artificial Intelligence · doi:10.1609/aaai.v35i1.16085 · Cited by 58
Fromin vivotoin vitro/in silicoADME: progress and challenges
Waterbeemd, H. V. D. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.1.1 · Cited by 44
The role of DMPK science in improving pharmaceutical research and development efficiency
Mak, K., Epemolu, O., & Pichika, M. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.005 · Cited by 30
Gajda, S., & Chlebuś, M. (2022) · Sensors · doi:10.3390/s22176361 · Cited by 6
Cited by
Recent advances in AI-based toxicity prediction for drug discovery
Lee, H., Kim, J., Kim, J.-W., & Lee, Y. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1632046 · Cited by 76
Large Language Model Agent for Modular Task Execution in Drug Discovery
Ock, J., Meda, R. S., Badrinarayanan, S., Aluru, N. S., Chandrasekhar, A., & Barati Farimani, A. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02454 · Cited by 5
Metadata
- Authors
- Myung, Y., de Sá, A. G. C., & Ascher, D. B.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-04-18
- Volume
- 52
- Issue
- W1
- Pages
- W469-W475
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W4394918443
- Cited by
- 337
- References
- 42
- FWCI
- 66.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.